A combination of SRC and MEK inhibitors has also proved beneficial in the treatment of breast cancer cells, where the combination of selumetinib and saracatinib induced apoptosis and reduced the initiation of both dormant and metastatic tumour cells, leading to diminished lung metasteses, compared to saracatinib alone [50]. This evidence concerns the gene MAP2K7 and breast carcinoma.